| Study | N (T/C) | Physical | Clinical stage | Treatment of experimental group | Treatment of control group | Outcomes |
| Cheng 2019 [12] | 43/43 | NR | III, IV | GP + SMI (50 mL/d, d1-d14) | GP | ①③④⑤⑥⑦⑧⑨ | Chen 2018 [13] | 48/48 | KPS ≥60 | III, IV | DP + SMI (100 mL/d, d1-d21) | DP | ① | Zhang 2018 [14] | 30/30 | NR | IIb, IIIa, IIIb | GP + SMI (100 mL/d, d1-d14) | GP | ①② | Zhang 2018 [15] | 57/57 | KPS ≥60 | I, II, III, IV | GP + SMI (50 mL/d, d1-d28) | GP | ④⑤⑥ | Xue 2007 [16] | 30/30 | KPS ≥60 | III, IV | NP + SMI (60 mL/d, d1-d10) | NP | ① | Zhou 2007 [17] | 32/30 | NR | IIIb, IV | GP + SMI (60 mL/d, d1-d21) | GP | ①②④⑤⑥⑦⑧⑨ | Hu 2008 [18] | 40/40 | KPS <70 | III, IV | NP + SMI (40 mL/d, d1-d28) | NP | ①③ | Wei 2008 [19] | 30/30 | KPS ≥60 | III, IV | NP + SMI (60 mL/d, d1-d14) | NP | ① | Zhao 2008 [20] | 56/56 | KPS ≥60 | NR | NP + SMI (50 mL/d, d1-d15) | NP | ②④⑨ | Feng 2009 [21] | 85/80 | NR | III, IV | GP + SMI (100 mL/d, d1-d15) | GP | ②④⑥⑨ | Shi 2008 [22] | 30/30 | KPS ≥60 | III, IV | NP + SMI (60 mL/d, d1-d30) | NP | ④⑤⑥⑨ | Tong 2009 [23] | 61/60 | KPS ≥60 | III, IV | GP + SMI OR TP + SMI OR NP + SMI(30 mL/d, d1-d10) | GP OR TP OR NP | ①②④ | Zhong 2009 [24] | 31/30 | KPS ≥50 | III, IV | GP + SMI (50 mL/d, d1-d10) | GP | ①②③ | Guo 2010 [25] | 31/31 | KPS ≥70 | IIIa, IIIb, IV | TP + SMI (50 mL/d, d1-d14) | TP | ①②⑥⑨ | Wei 2010 [26] | 30/30 | KPS ≥60 | IIIa, IIIb, IV | TP + SMI (60 mL/d, d1-d30) | TP | ②④⑥⑨ | Zheng 2010 [27] | 30/30 | KPS ≥60 | IIIb, IV | DP + SMI (60 mL/d, d1-d15) | DP | ①④⑨ | Chen 2011 [28] | 64/50 | KPS ≥60 | IIIb, IV | GP + SMI OR TC + SMI OR NP + SMI (50 mL/d, d1-d14) | GP OR TC OR NP | ⑤⑥ | Ji 2011 [29] | 20/20 | NR | IIIb, IV | GP + SMI (60 mL/d, d1-d28) | GP | ①④⑥⑨ | Liu 2011 [30] | 30/30 | KPS ≥60 | IIIb, IV | TP + SMI (60 mL/d, d1-d15) | TP | ①②④⑦⑨ | Lu 2011 [31] | 30/30 | KPS ≥60 | IIIa, IIIb, IV | NP + SMI (50 mL/d, d1-d14) | NP | ②④⑥ | Fu 2012 [32] | 30/30 | KPS ≥60 | IIIa, IIIb, IV | GP + SMI (60 mL/d, d1-d15) | GP | ①④⑤⑥⑦⑧⑨ | Li 2012 [33] | 25/25 | KPS ≥60 | IIIb, IV | GP + SMI (50 mL/d, d1-d10) | GP | ①④⑤⑦⑧⑨ | Li 2013 [34] | 54/53 | KPS ≥60 | IIIb, IV | GP + SMI (50 mL/d, d1-d10) | GP | ①②④⑨ | Shang 2012 [35] | 25/25 | KPS ≥60 | IIIb, IV | GP + SMI (50 mL/d, d1-d10) | GP | ① | Chen 2013 [36] | 29/28 | NR | IIIb, IV | TP + SMI (d1-d7) | TP | ④⑥ | Jiang 2013 [37] | 30/30 | KPS ≥60 | IIIb, IV | GP + SMI OR DP + SMI (50 mL/d, d1-d14) | GP OR DP | ②④⑥⑦⑧⑨ | Yao 2013 [38] | 24/24 | KPS ≥60 | IIIa, IIIb, IV | NP + SMI (40–60 mL/d, d1-d10) | NP + SMI | ① | Zhang 2013 [39] | 27/27 | KPS ≥60 | III, IV | NP + SMI (60 mL/d, d1-d14) | NP + SMI | ④⑥ | Shen 2014 [40] | 25/25 | KPS ≥60 | IIIb, IV | DP + SMI (100 mL/d, d1-d14) | DP | ①④⑤⑥ | Yao 2014 [41] | 40/40 | NR | IIIb, IV | NP + SMI (60 mL/d, d1-d10) | NP | ①④⑥⑨ | Sun 2015 [42] | 40/40 | KPS ≥60 | IIIb, IV | GP + SMI (40 mL/d, d1-d10) | GP | ①②④⑤⑥ | Hua 2016 [43] | 40/40 | NR | NR | GP + SMI (40 mL/d, d1-d7) | GP | ①④⑥⑨ | Li 2016 [44] | 73/40 | KPS ≥60 | IIIa, IIIb, IV | GP + SMI (50 mL/d, d1-d10) | GP | ①③ | Wang 2016 [45] | 24/24 | KPS ≥60 | IIIb, IV | TP + SMI (100 mL/d, d1-d7) | TP | ①③④⑤ | Xu 2016 [46] | 23/23 | KPS ≥60 | IIIb, IV | GP + SMI (40 mL/d, d1-d10) | GP | ①② | Luo 2017 [47] | 81/81 | NR | IIIa, IIIb, IV | DP + SMI (40 mL/d, d1-d30) | DP | ③④⑥⑨ | Wu 2017 [48] | 30/30 | KPS ≥70 | III, IV | NP + SMI OR GP + SMI (50 mL/d, d1-d28) | NP OR GP | ①④⑤⑥⑦⑧⑨ |
|
|